Pfizer's Lung Cancer Drug Trial Misses Endpoint
By Dean Seal
Pfizer said the latest trial of one of its lung cancer treatments missed its primary endpoint.
The drugmaker reported Wednesday that the Phase 3 study of sigvotatug vedotin, which is being developed to treat locally advanced, unresectable or metastatic non-squamous non-small cell lung cancer, failed to show statistically significant improvement in overall survival compared with the widely used chemotherapy drug docetaxel.
"Patients with previously treated advanced NSCLC are a historically difficult-to-treat population, and there is clearly more work to be done to improve the outcomes for this population," Pfizer Chief Oncology Officer Jeff Legos said.
Patients who had only received one previous line of therapy, which made up about two-thirds of the enrollment, did achieve strong efficacy outcomes from sigvotatug vedotin compared with an established standard of care, Legos said. And the drug had a manageable safety profile.
Pfizer is still running a separate trail testing sigvotatug vedotin, in combination with the drug pembrolizumab, as a first-line treatment for patients who haven't received prior therapies yet.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 22, 2026 17:09 ET (21:09 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
33 Undervalued Stocks to Buy Before the Market Shifts Again
United States